Exact Sciences holds secondary stock offering
Seeking more money to market its Cologuard cancer-screening test, Madison-based Exact Sciences is conducting a secondary public stock offering that will close on or about Dec. 19. Four million common shares have been sold to Jefferies and Robert W. Baird & Co., which will act as underwriters. If demand dictates, the company may make an additional 600,000 shares available. If it sells all the shares, including the additional 600,000, the company will raise $118 million.